[go: up one dir, main page]

PE20010052A1 - Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht - Google Patents

Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht

Info

Publication number
PE20010052A1
PE20010052A1 PE2000000368A PE0003682000A PE20010052A1 PE 20010052 A1 PE20010052 A1 PE 20010052A1 PE 2000000368 A PE2000000368 A PE 2000000368A PE 0003682000 A PE0003682000 A PE 0003682000A PE 20010052 A1 PE20010052 A1 PE 20010052A1
Authority
PE
Peru
Prior art keywords
alkyl
aryl
azepinindol
agonists
antagonists
Prior art date
Application number
PE2000000368A
Other languages
English (en)
Inventor
Jackson B Hester Jr
Bruce N Rogers
Eric Jon Jacobsen
Michael Dalton Ennis
Kristine E Frank
Velde Susan L Vander
Brad A Acker
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of PE20010052A1 publication Critical patent/PE20010052A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A DERIVADOS DE 1,2,3,4,5,6-HEXAHIDROAZEPIN-[4,5-b]INDOL QUE TIENEN UN ANILLO PARA UNIR LA POSICION 6 Y 7 DE FORMULA I DONDE R1 ES OH, NITRO, HALOGENO, CN, TRIFLUOROMETILO, S(O)mNRaRb, NRcRd, S(O)mRe, ENTRE OTROS; R2 ES H, ALQUILO C1-C7, ALCANOILO C1-C7, ALCOXICARBONILO C1-C7, ENTRE OTROS; X E Y JUNTOS SON UNA CADENA CON ATOMOS DE C OPCIONALMENTE CONTIENE UN GRUPO -O-, -S-, -SO-, -SO2-, NRf OPCIONALMENTE SUSTITUIDA CON OXO, OH, ALCOXILO C1-C7; m ES 0-2; n ES 0-3; CADA Ra Y Rb SON H, ALQUILO C1-C7, ARILO, ARILALQUILO C1-C7, HETEROARILO, HETEROARIL ALQUILO C1-C7; Ra Y Rb JUNTO CON N FORMAN PIRROLIDINO, PIPERIDINO, MORFOLINO, TIOMORFOLINO; CADA Rc Y Rd SON H, ALQUILO C1-C7, ALCANOILO C1-C7, ALCOXICARBONILO C1-C7, ARILO, O JUNTO CON N FORMAN PIRROLIDINO, PIPERIDINO, MORFOLINO, TIOMORFOLINO, ENTRE OTROS; Re ES H, ALQUILO C1-C7, ARILO, ENTRE OTROS; Rf ES H, ALQUILO C1-C7, ARILO, ARILALQUILO C1-C7, ENTRE OTROS; CON LA CONDICION QUE Y NO ES OXI, TIO, SULFINILO, NRf, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 5,6,9,10,11,12-HEXAHIDRO-4H,8H-AZEPIN[4`,5':4,5]PIRROL[3,2,1-ij]QUINOLINA, 2-METIL-5,6,9,10,11,12-HEXAHIDRO-4H,8H-AZEPIN[4',5':4,5]PIRROL[3,2,1-ij]-QUINOLINA, ENTRE OTROS. LOS COMPUESTOS I SON LIGANDOS DE SEROTONINA 5-HT Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL, SUENO, DEPRESION
PE2000000368A 1999-04-23 2000-04-19 Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht PE20010052A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13081199P 1999-04-23 1999-04-23

Publications (1)

Publication Number Publication Date
PE20010052A1 true PE20010052A1 (es) 2001-01-27

Family

ID=22446459

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000368A PE20010052A1 (es) 1999-04-23 2000-04-19 Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht

Country Status (20)

Country Link
EP (1) EP1173440B1 (es)
JP (1) JP2002543080A (es)
KR (1) KR20020005708A (es)
CN (1) CN1183132C (es)
AR (1) AR023574A1 (es)
AT (1) ATE276255T1 (es)
AU (1) AU760943C (es)
BR (1) BR0009983A (es)
CA (1) CA2367682A1 (es)
DE (1) DE60013803T2 (es)
DK (1) DK1173440T3 (es)
EC (1) ECSP003426A (es)
ES (1) ES2226822T3 (es)
HK (1) HK1045512B (es)
NZ (1) NZ514553A (es)
PE (1) PE20010052A1 (es)
PT (1) PT1173440E (es)
SI (1) SI1173440T1 (es)
WO (1) WO2000064899A1 (es)
ZA (1) ZA200108636B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
HK1042480A1 (zh) 1999-06-15 2002-08-16 Bristol-Myers Squibb Pharma Company 取代的稠杂环γ-咔啉
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
WO2002004456A1 (en) 2000-07-06 2002-01-17 Pharmacia & Upjohn Company SUBSTITUTED 2,3,7,8,9,10,11,12-OCTAHYDROAZEPINO[4,5-b]PYRANO[3,2-e]INDOLES
WO2002024700A2 (en) 2000-09-20 2002-03-28 Pharmacia & Upjohn Company SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES
AR031200A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
US6777407B2 (en) 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6858604B2 (en) 2000-11-03 2005-02-22 Wyeth Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
IL156354A0 (en) * 2000-12-20 2004-01-04 Bristol Myers Squibb Co Pyridoindole derivatives and pharmaceutical compositions containing the same
US20020160999A1 (en) * 2001-01-08 2002-10-31 Jacobsen Susan Fox Substituted indolines
US6720316B2 (en) * 2001-08-06 2004-04-13 Pharmacia & Upjohn Company Therapeutic 5-HT ligand compounds
US20030060462A1 (en) * 2001-08-06 2003-03-27 Hoffman Robert L. Therapeutic compounds
BR0212676A (pt) * 2001-09-21 2006-05-23 Upjohn Co compostos terapêuticos ligantes de 5-ht, composições farmacêuticas compreendendo tais compostos e seus usos
MXPA04003594A (es) * 2001-10-18 2004-07-30 Upjohn Co Azaindoles e indolinas tetraciclicas que tienen actividad en serotonina 5-ht-2.
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US7893051B2 (en) * 2006-01-19 2011-02-22 Athersys, Inc. Thiophenyl and pyrrolyl azepines as serotonin 5-HT2c receptor ligands and uses thereof
US8158617B2 (en) 2006-05-16 2012-04-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
KR102065319B1 (ko) 2007-03-12 2020-01-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND ITS USE
ES2523580T3 (es) 2008-01-11 2014-11-27 Albany Molecular Research, Inc. Piridoindoles substituidos con (1-Azinona)
ES2568262T3 (es) * 2009-04-23 2016-04-28 Abbvie Inc. Moduladores de receptores de 5-HT y sus métodos de uso
EP2448585B1 (en) 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
US20150080404A1 (en) 2012-04-14 2015-03-19 Intra-Cellular Therapies, Inc. Novel compositions and methods
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
PL3076967T3 (pl) 2013-12-03 2021-12-20 Intra-Cellular Therapies, Inc. Metody leczenia objawów rezydualnych schizofrenii
EP3125892A4 (en) 2014-04-04 2017-12-27 Intra-Cellular Therapies, Inc. Organic compounds
MX388258B (es) 2014-04-04 2025-03-19 Intra Cellular Therapies Inc Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
HUE053737T2 (hu) 2016-01-26 2021-07-28 Intra Cellular Therapies Inc Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
JP2019513143A (ja) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規塩類および結晶
EP3436016B1 (en) 2016-03-28 2022-04-27 Intra-Cellular Therapies, Inc. Novel co-crystals
CN105837571A (zh) * 2016-04-23 2016-08-10 何华琼 盐酸倍他司汀的药物组合物及其在生物医药中的应用
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
KR20240141212A (ko) 2017-03-24 2024-09-25 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 조성물 및 방법
WO2019023062A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
AU2018307480B2 (en) 2017-07-26 2023-11-23 Intra-Cellular Therapies, Inc. Organic compounds
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CN112040940A (zh) 2018-03-23 2020-12-04 细胞内治疗公司 有机化合物
JP7476115B2 (ja) 2018-06-06 2024-04-30 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規の塩および結晶
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
JP7483671B2 (ja) 2018-06-11 2024-05-15 イントラ－セルラー・セラピーズ・インコーポレイテッド 置換ヘテロ環縮合ガンマ－カルボリン類合成
EP3843729A4 (en) 2018-08-29 2022-06-01 Intra-Cellular Therapies, Inc. NEW COMPOSITIONS AND METHODS
WO2020047407A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
CN118873536A (zh) 2018-08-31 2024-11-01 细胞内治疗公司 新方法
AU2019403149B2 (en) 2018-12-17 2025-04-03 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
WO2020131911A1 (en) 2018-12-17 2020-06-25 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
AU2020229779B9 (en) 2019-02-27 2025-09-18 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
WO2021119334A1 (en) 2019-12-11 2021-06-17 Intra-Cellular Therapies, Inc. Organic compound
WO2023114313A1 (en) 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
MX2024007220A (es) * 2021-12-15 2024-08-27 Delix Therapeutics Inc Psicoplastogenos de pirrolidina fusionada y sus usos.
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839357A (en) * 1966-05-10 1974-10-01 Upjohn Co 1,2,3,4,5,6-hexahydroazepino(4,5-b)indoles
US3676558A (en) * 1970-08-28 1972-07-11 Upjohn Co Anorexigenic compositions comprising 6-alkyl-1,2,3,4,5,6-hexahydroazepino 4,5-indoles as active ingredient and process of treatment
EP0377238A1 (en) * 1988-12-22 1990-07-11 Duphar International Research B.V New annelated indolo (3,2-c)-lactams

Also Published As

Publication number Publication date
NZ514553A (en) 2003-10-31
SI1173440T1 (en) 2005-02-28
AU760943B2 (en) 2003-05-22
DE60013803T2 (de) 2005-11-17
CN1348454A (zh) 2002-05-08
HK1045512B (zh) 2005-09-02
ATE276255T1 (de) 2004-10-15
AU760943C (en) 2003-12-04
DE60013803D1 (de) 2004-10-21
AU4363700A (en) 2000-11-10
ES2226822T3 (es) 2005-04-01
ZA200108636B (en) 2003-02-19
JP2002543080A (ja) 2002-12-17
WO2000064899A1 (en) 2000-11-02
EP1173440A1 (en) 2002-01-23
ECSP003426A (es) 2000-10-24
AR023574A1 (es) 2002-09-04
EP1173440B1 (en) 2004-09-15
CN1183132C (zh) 2005-01-05
HK1045512A1 (en) 2004-10-15
PT1173440E (pt) 2004-12-31
BR0009983A (pt) 2002-04-16
DK1173440T3 (da) 2004-12-20
KR20020005708A (ko) 2002-01-17
CA2367682A1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
PE20010052A1 (es) Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht
Chu et al. Structure-activity relationships of the fluoroquinolones
Katritzky et al. Synthesis of heterocycles mediated by benzotriazole. 2. Bicyclic systems
PE20030848A1 (es) Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1
AR061867A1 (es) Derivados de (4,5') bipirimidil 6,4' - diamina como inhibidores de proteinquinasa
PE20030847A1 (es) Aza-arilpiperazinas como ligandos del receptor 5ht2
PE20060775A1 (es) Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa
RU2010138928A (ru) Соединение бензодиазепина и фармацевтическая композиция
PE20110671A1 (es) Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina
KR920701204A (ko) 중추 신경계 활성을 갖는 헤테로사이클릭 아민
AR035666A1 (es) Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
AR035774A1 (es) Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento
PE20040593A1 (es) DERIVADOS DE DIHIDROPIRIMIDO[4,5-d]PIRIMIDONA AMINO SUSTITUIDOS COMO INHIBIDORES DE TIROSINACINASAS DEL GRUPO SRC
AR040567A1 (es) Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6
AR029454A1 (es) Derivados de piperazina sustituidos, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos
PE20080403A1 (es) Derivados heterociclicos fusionados y metodos de uso
PE20081346A1 (es) Derivados de espiroindolinona como antagonistas de mdm2
PE20020485A1 (es) Derivados de quinolina y quinazolina como antagonistas del neuropeptido y
BR0309463A (pt) Derivados de 1,2,3,4,7,8-hexaidro-6h-[1,4]diazepino[6,7,1-ij]quinolina como agentes antipsicóticos e antiobesidade
AR043181A1 (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxiptamina-6
AR052312A1 (es) 2- anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y medicamentos preparados en base al compuesto
AR017189A1 (es) Antagonistas del receptor de trombina triciclico sustituido, composicion farmaceutica que lo contiene y su uso para la manufactura de un medicamento
PE20001537A1 (es) 4-alquenil y 4-alquinil oxindoles como inhibidores de quinasas dependientes de ciclina
AR037906A1 (es) Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR049664A1 (es) Metodos anticonceptivos con antagonistas del receptor de progesterona derivados del indol y de la benzo[d][1, 3]oxazina y kits.

Legal Events

Date Code Title Description
FC Refusal